Tesetaxel
- Generic Name
- Tesetaxel
- Drug Type
- Small Molecule
- Chemical Formula
- C46H60FN3O13
- CAS Number
- 333754-36-2
- Unique Ingredient Identifier
- UG97LO5M8Y
- Background
Tesetaxel has been used in trials studying the treatment of Cancer, Melanoma, Prostate Cancer, Gastric Carcinoma, and Advanced Melanoma, among others.
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT04312282
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 294
- Registration Number
- NCT03952325
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
🇸🇬National Cancer Centre Singapore, Singapore, Singapore
🇺🇸Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States
Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT03858972
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇨🇦Hopital Maisonneuve-Rosemont, Montréal, Canada
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 685
- Registration Number
- NCT03326674
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Arizona Oncology Associates, P.C. - HOPE, Tucson, Arizona, United States
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
- Conditions
- Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 213
- Registration Number
- NCT01609127
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 580
- Registration Number
- NCT01573468
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Study of Tesetaxel in Japanese Patients With Solid Tumors
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT01337310
- Locations
- 🇯🇵
Kinki University School of Medicine, Osaka-fu, Japan
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 9
- Registration Number
- NCT01315431
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 57
- Registration Number
- NCT01296243
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
- Conditions
- Breast Neoplasm
- Interventions
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Genta Incorporated
- Target Recruit Count
- 81
- Registration Number
- NCT01221870
- Locations
- 🇺🇸
The Moses H. Cone Regional Cancer Center, Greensboro, North Carolina, United States
🇺🇸The West Clinic, Memphis, Tennessee, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.